Divi’s Laboratories (DIVISLAB) investor relations material

Executive summary

• Maintained stable performance in generics, supported by backward integration and process efficiencies.

• Custom synthesis segment saw active engagement in RFPs and customer visits, with several projects progressing toward commercialization in the next year.

• Peptide chemistry and nutraceuticals segments advanced, with capacity expansion and strong customer program support.

• Unit 3 at Kakinada strengthened backward integration and supply chain; successful US FDA inspection at Unit 1.

• Consolidated total income for Q3 FY26 was ₹2,692 crores, up from ₹2,401 crores in Q3 FY25; nine-month total income reached ₹8,081 crores, up from ₹7,041 crores year-over-year.

Financial highlights

• Q3 FY26 consolidated total income: INR 2,692 crores (up from INR 2,401 crores YoY); profit before exceptional item and tax: INR 854 crores (up from INR 726 crores YoY).

• Exceptional item: one-time INR 74 crores employee benefit obligation due to new Labour Codes.

• Q3 profit after tax: INR 583 crores (vs. INR 589 crores YoY); material consumption: 36.3% of sales (down from 39.8% YoY).

• Nine-month total income: INR 8,081 crores (up from INR 7,041 crores YoY); profit after tax: INR 1,817 crores (vs. INR 1,529 crores YoY).

• Forex gains for Q3 FY26 were ₹19 crores consolidated and ₹18 crores standalone, both higher than the previous year.

Outlook and guidance

• Operating environment for raw material pricing and availability expected to remain broadly stable over the next six months.

• Double-digit growth trajectory expected to continue, with no major disruption anticipated from product lifecycle changes.

• Commercialization of three dedicated custom synthesis projects expected in Q3-Q4 of calendar year 2027, subject to regulatory approvals.

• Management continues to monitor the finalization of new labour codes and will adjust for any further impacts as regulations are clarified.